Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease. The company released its 2Q2024 earnings and highlighted advances made with its signature treatment-Lomecel-B. The treatment has made significant progress and received multiple FDA designation for both Alzheimer's Disease and the devastating HLHS.